A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
- PMID: 30054476
- PMCID: PMC6063898
- DOI: 10.1038/s41467-018-05373-4
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
Abstract
Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade, but its treatment benefits are limited by acquired resistance, a process that remains incompletely understood. Here we report that an enhancer, located between the promoters of marker of proliferation Ki67 (MKI67) and O6-methylguanine-DNA-methyltransferase (MGMT) genes, is activated in TMZ-resistant patient-derived xenograft (PDX) lines and recurrent tumor samples. Activation of the enhancer correlates with increased MGMT expression, a major known mechanism for TMZ resistance. We show that forced activation of the enhancer in cell lines with low MGMT expression results in elevated MGMT expression. Deletion of this enhancer in cell lines with high MGMT expression leads to a dramatic reduction of MGMT and a lesser extent of Ki67 expression, increased TMZ sensitivity, and impaired proliferation. Together, these studies uncover a mechanism that regulates MGMT expression, confers TMZ resistance, and potentially regulates tumor proliferation.
Conflict of interest statement
The authors declare the following: a preliminary patent application was filed based on the current studies. The authors declare no other competing interests.
Figures
Similar articles
-
Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.Int J Mol Sci. 2022 Jan 28;23(3):1545. doi: 10.3390/ijms23031545. Int J Mol Sci. 2022. PMID: 35163465 Free PMC article.
-
MGMT Status as a Clinical Biomarker in Glioblastoma.Trends Cancer. 2020 May;6(5):380-391. doi: 10.1016/j.trecan.2020.02.010. Epub 2020 Mar 27. Trends Cancer. 2020. PMID: 32348734 Free PMC article. Review.
-
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.Oncogene. 2020 Apr;39(15):3041-3055. doi: 10.1038/s41388-020-1208-5. Epub 2020 Feb 17. Oncogene. 2020. PMID: 32066879 Free PMC article.
-
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Int J Oncol. 2015 Aug;47(2):417-28. doi: 10.3892/ijo.2015.3026. Epub 2015 May 29. Int J Oncol. 2015. PMID: 26035292 Free PMC article. Review.
-
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.Clin Cancer Res. 2012 Aug 1;18(15):4070-9. doi: 10.1158/1078-0432.CCR-12-0560. Epub 2012 Jun 6. Clin Cancer Res. 2012. PMID: 22675172 Free PMC article.
Cited by
-
Temperature-Wise Calibration Increases the Accuracy of DNA Methylation Levels Determined by High-Resolution Melting (HRM).Int J Mol Sci. 2024 May 7;25(10):5082. doi: 10.3390/ijms25105082. Int J Mol Sci. 2024. PMID: 38791122 Free PMC article.
-
Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT).J Neurooncol. 2024 May 19. doi: 10.1007/s11060-024-04708-0. Online ahead of print. J Neurooncol. 2024. PMID: 38762829
-
USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.CNS Neurosci Ther. 2024 Apr;30(4):e14711. doi: 10.1111/cns.14711. CNS Neurosci Ther. 2024. PMID: 38644551 Free PMC article.
-
p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.BMC Cancer. 2024 Mar 7;24(1):317. doi: 10.1186/s12885-024-12017-y. BMC Cancer. 2024. PMID: 38454344 Free PMC article.
-
Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.CNS Neurosci Ther. 2024 Mar;30(3):e14649. doi: 10.1111/cns.14649. CNS Neurosci Ther. 2024. PMID: 38448295 Free PMC article.
References
-
- Moradi, M. et al. The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J. Cell. Physiol.233, 378-386 (2018). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous